$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of 2027 NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8Bio” or the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company develo ...

Core Insights - IN8bio, Inc. presented new preclinical data for its γδ T cell engager program, INB-619, at the 2025 ACR Convergence Meeting, highlighting its potential in treating cancer and autoimmune diseases [1][2] Preclinical Data - INB-619 demonstrated complete elimination of B cells in preclinical SLE donor models, showing efficacy comparable to FDA-approved CD19 and CD20 engagers like blinatumomab and mosunetuzumab [2][8] - The compound exhibited minimal secretion of adverse cytokines, such as IL-6, at significantly lower concentrations than currently marketed compounds [2][6] Mechanism and Safety Profile - INB-619's design allows for higher doses and deeper B cell depletion, potentially leading to an immune reset not observed with other protein engagers [3][4] - The therapy selectively expanded γδ T cells without activating CD4+ or CD8+ αβ T cells, indicating a potentially improved safety and tolerability profile [3][4] Unique Properties - INB-619 is a first-in-class, CD19-targeted, pan-γδ T cell engager that activates and expands both V-delta-1 and V-delta-2 T cell subsets, leading to effective B cell depletion [4][8] - Unlike conventional T cell engagers, INB-619 does not engage the CD3 receptor, significantly reducing the risk of toxicities such as cytokine release syndrome and neurotoxicity [5][6] Clinical Implications - The results suggest that INB-619 could transform the treatment landscape for autoimmune diseases by safely eliminating pathogenic B cells and driving immune reset [6][8] - The data indicated robust, dose-dependent B cell killing and γδ T cell expansion, maintaining a favorable cytokine profile consistent with γδ T cell biology [6][8] Company Overview - IN8bio is a clinical-stage biopharmaceutical company focused on developing γδ T cell therapies for unmet medical needs, with additional programs targeting acute myeloid leukemia and glioblastoma [7]